Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

allowing it to extend the patent life of a blockbuster line of medications, internal documents show. By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

There, he had access to a great diversity of science led by the ... role in helping bring new life-saving treatments to cancer patients." Originally published by Gilead Sciences View additional ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...

Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the ...

Indian Patent Office to hear objections against Gilead's Lenacapavir patent claims, crucial for affordable HIV treatment ...

The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...